Natco Pharma Share Price Jumps 11.78% to ₹920.90 After CDSCO Approves Semaglutide In India

Natco Pharma Ltd (NSE: NATCOPHARM) surged 11.78% to ₹920.90 on an intraday basis as of 10:59 AM IST on 16 February 2026, compared with its previous close of ₹823.85. The stock gained ₹97.05 during the session, following a regulatory approval announcement disclosed to exchanges on 14 February 2026.

Why Natco Pharma Share Price Rose

The rally followed Natco Pharma’s disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, stating that it received approval from the Central Drugs Standard Control Organisation (CDSCO) for Semaglutide in India.

According to the company’s press release dated 14 February 2026, Natco received approval to manufacture and market generic Semaglutide injection in India and plans to launch the product in March 2026. Semaglutide is indicated for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Natco Pharma Stock Performance Snapshot

As of 10:59 AM IST on 16 February 2026, Natco Pharma was trading at ₹920.90, up 11.78% from the previous close of ₹823.85. The stock touched a high of ₹922.80 and a low of ₹828.00 during the session.

The company’s market capitalisation stood at approximately ₹16.49K crore, with a price-to-earnings ratio of 10.59, based on available exchange data.

What this Means for Investors

The CDSCO approval enables Natco Pharma to enter the domestic Semaglutide market, expanding its diabetes portfolio. The planned March 2026 launch may support incremental domestic revenue, subject to market uptake and competitive dynamics.

As per the company’s disclosure, the approval pertains specifically to manufacturing and marketing in India. Investors may track execution timelines, pricing strategy, and volume traction post-launch for further clarity on financial impact.

Broader Market and Sectoral Context

The sharp move positioned Natco Pharma among notable gainers in the pharmaceutical segment during the morning trade. The stock’s double-digit rise contrasted with broader benchmark movements, indicating a company-specific trigger linked to regulatory approval.

Within the pharma space, regulatory clearances and product launches typically drive near-term price reactions, particularly for complex generics and chronic therapy segments such as diabetes.

About the Company

Natco Pharma Limited (BSE: 524816; NSE: NATCOPHARM) is headquartered in Hyderabad, India. The company develops, manufactures and markets generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.

Natco operates nine manufacturing facilities and two R&D centres in India. Its facilities are approved by regulatory authorities including the US FDA, ANVISA Brazil, Health Canada and WHO, and the company caters to more than 50 global markets.

Natco Pharma’s 11.78% intraday surge to ₹920.90 on 16 February 2026 followed its regulatory disclosure confirming CDSCO approval for Semaglutide in India. The company plans to launch the product in March 2026. The price movement reflects a market response to the regulatory clearance, with investors expected to monitor launch execution and revenue contribution in the coming quarters.

Source:  

• https://www.bseindia.com/xml-data/corpfiling/AttachLive/b6c90a85-70f8-463c-9d7e-ac74e6aeb477.pdf
• https://www.bseindia.com/stock-share-price/equity/scripcode/524816/financials-annual-reports/